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Abstract: 
 
Nurse practitioners (NPs) frequently treat adults with atrial fibrillation. With new oral 
antithrombotic agents available, NPs need to be knowledgeable of treatment options to prevent 
stroke and systemic emboli. This article reviews the latest American College of Cardiology 
Foundation/American Heart Association guideline on the management of atrial fibrillation. 
Emphasis is placed on the changing landscape of pharmacological agents. Use of guideline-
directed medical therapy will ultimately improve patients’ quality of life and prevent stroke and 
premature death. 
 
Keywords: anticoagulation | atrial fibrillation | clinical guidelines | nurse practitioner | stroke 
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Article:  
 
Atrial fibrillation (AF), the most common, sustained cardiac dysrhythmia in adults, is a condition 
that nurse practitioners (NPs) frequently encounter in clinical practice. Estimates of AF 
prevalence in the United States ranged from 2.7 million to 6.1 million individuals in 2010 and 
is predicted to double by 2050.1 Furthermore, the Framingham Heart Study calculated that the 
lifetime risk for a 40-year-old man to develop AF is 26% and slightly less for a woman 
(23%).1 Most adults develop AF later in life; the average age for men is 67, for women age 
75.1 In addition, the prevalence is greater for whites compared to blacks or other 
races.1 However, blacks usually develop AF at a younger age. 
 
Risk prediction models have been developed that identify risk factors for new-onset AF.1 
Table 1 displays the standard risk factors for AF. An interactive risk score calculator, from the 
Framingham Heart Study, is available for NPs 
at http://framinghamheartstudy.org/risk/atrial.html. 
 
 
Table 1. Standard Risk Factors for Atrial Fibrillation (AF) 
• Advanced age 
• Male sex 
• European ancestry 
• Body size (BMI ≥ 30 kg/m2 or increased height) 
• Elevated SBP (≥ 160 mm Hg) or treatment for HTN 
• Prolonged PR interval (≥ 200 ms) 
• Diabetes 
• Presence of CVD (CHD, HF, or valvular heart disease) 
• Less common risk factors: hyperthyroidism (may be subclinical), chronic kidney disease, or 
heavy alcohol consumption 
BMI = body mass index; CHD = coronary heart disease; CVD = cardiovascular disease; HF = 
heart failure; HTN = hypertension; SBP = systolic blood pressure. 
Data from Go et al1and Furie et al.2 
 
AF varies in presentation, from being asymptomatic to completely disabling. Yet, regardless of 
how asymptomatic a patient is, AF is associated with increased mortality and morbidity. AF 
nearly doubles a patient’s risk of death (odds ratio of 1.5 for men; odds ratio of 1.9 for women) 
and increases the risk of ischemic stroke by 4-5, compared to those without AF.1However, the 
risk of stroke in patients with AF is quite variable, ranging from 1%-20% annually, depending on 
comorbidities, age, and history of previous stroke.2 In addition, persons with AF are twice as 
likely to have dementia and more likely to develop heart failure (HF) (∼40% of those with AF).1 
 
Table 2. Classification of Atrial Fibrillation (AF) 
Type of AF Characteristics 
Paroxysmal 
AF 
Recurrent AF; lasting < 7 days (most < 24 hours); spontaneously returns to sinus 
rhythm without treatment 
Persistent 
AF 
Recurrent AF; lasting ≥ 7 days, requiring treatment to revert to sinus rhythm 
Permanent 
AF 
AF that is permanent; no treatment is able to restore sinus rhythm (cardioversion 
has failed or has not been attempted). Includes cases of long-standing AF (> 1 
year) 
Data from Lubitz et al3and Fuster et al.4 
 
AF Classification 
 
A variety of clinical and research classification schemes for AF have been used to inform clinical 
decision making, including schemes that classify AF based on etiology, pathophysiology, 
symptoms, temporal patterns, and quality of life.3 Traditionally, most clinicians have classified 
AF as acute (lasting < 48 hours) versus chronic; however, new classification schemes have 
gradually led to disuse of these terms.3 To be clinically useful, a temporal rhythm-based pattern 
classification should be used to characterize the type of arrhythmia at the time of presentation (at 
the moment the NP examines the patient).4 The NP should distinguish whether the patient with 
AF has a first-detected (or first diagnosed) episode versus a recurrent episode (having 2 or more 
episodes) regardless of symptoms.3,4 First detected AF may be further subclassified as 
paroxysmal or persistent (Table 2) .3,4 Likewise, recurrent episodes may be further subclassified 
as paroxysmal or persistent AF and may progress to permanent AF.4 
 
Patients may have more than one type of AF over their lifetime. For example, an individual may 
have paroxysmal episodes lasting seconds or hours for years; then over time, as his or her atrium 
experiences electrical and mechanical remodeling from the AF, he or she may have more 
persistent episodes or develop permanent AF. Because patients may have more than one type of 
AF, they should be categorized by the most frequent type with which they present.4 
 
Another term, “lone AF,” has been used to apply to young patients (< 60) who have AF yet no 
clinical or echocardiographic evidence of heart or lung disease, including hypertension.3,4 These 
patients generally have a more favorable diagnosis (in terms of mortality and risk of stroke or 
thromboembolism).4 However, it is debatable whether the use of this term is appropriate as a 
distinct subset of AF because individuals with lone AF may also be classified as one of the 
subtypes of recurrent AF.3 The remainder of this article will focus on the management of patients 
with recurrent AF (paroxysmal AF and persistent AF) and permanent AF. 
 
Although the amount of time the patient spends in AF may differ, the increased risk of ischemic 
stroke is about the same for paroxysmal, persistent, or permanent AF.1 Thus, nurse practitioners 
(NPs) need to remember that one of the most important treatment goals for all 3 types of chronic 
AF is to prevent stroke. Other major treatment goals are to control the ventricular heart rate 
(during episodes of AF) and restore sinus rhythm in persistent AF (in appropriate patients). 
 
Rate Control 
 
Reduction of the ventricular heart rate for patients in AF allows for adequate filling time to the 
ventricles and, in some cases, helps avoid rate-related ischemia.5 However, the optimal 
ventricular heart rate has not been definitively determined.5 Criteria for heart rate control are 
individualized but usually are between 60-80 beats per minute (bpm) at rest and 90-115 bpm 
during moderate levels of exercise.5 The 2013 American College of Cardiology Foundation 
(ACCF)/American Heart Association (AHA) practice guideline (a compilation of the 2006 and 
2011 recommendations for the management of patients with AF) indicates that there is no benefit 
to “strict rate control” (< 80 bpm at rest or < 110 bpm during a 6-minute walk), as opposed to 
“lenient rate control” (resting heart rate of < 110 bpm) in patients with stable persistent AF (left 
ventricular [LF] function > 0.40 and no or acceptable symptoms from the AF).6 
 
Rate control for patients in AF is generally obtained by either the use of a beta-blocker or a non-
dihydropyridine calcium channel blocker (CCB, primarily diltiazem or verapamil).6 In addition, 
digoxin is effective for controlling heart rate at rest in patients with AF and concurrent HF or for 
sedentary individuals.6 However, digitalis should not be the only medication used to control 
ventricular rate in patients with paroxysmal AF.6 Some patients may require a combination of 
digoxin and either a beta-blocker or a nondihydropyridine CCB to control heart rate at rest and 
with exercise.6 However, the dose of the combination therapy should be individualized to avoid 
bradycardia. If ventricular heart rate control does not offer symptomatic relief, then restoration of 
sinus rhythm becomes a treatment goal.4 
 
Restoration of Sinus Rhythm 
 
Not all patients with AF need to have sinus rhythm restored. For example, for patients who are 
not highly symptomatic or are elderly or generally sedentary, restoration of sinus rhythm is not 
generally needed. However, if a patient is highly symptomatic with recurrent AF, then 
maintenance of sinus rhythm to relieve symptoms may be required. However, maintaining sinus 
rhythm is a laudable goal in many. Early cardioversion may be necessary for patients with AF 
who have associated hypotension or worsening HF.4 
 
When considering pharmacologic cardioversion, the NP should screen for and treat any 
precipitating or reversible causes of AF before starting antiarrhythmic drug therapy.5Examples of 
reversible (secondary) causes include metabolic disorders (eg, thyroid dysfunction), sleep apnea, 
excessive alcohol consumption or illicit drug use, or myocardial ischemia. 
 
For patients who have been in AF for greater than 24-48 hours, it is important to make sure they 
have been adequately anticoagulated for 30 days before any attempts to restore sinus rhythm by 
cardioversion. For example, the international normalized ratio (INR) for patients on warfarin 
should be greater 2.0 for at least 2 weeks for 30 days before chemical or direct current 
cardioversion (DCCV). Likewise, patients who are on a newer antithrombotic agent (dabigatran 
[Pradaxa®], rivaroxaban [Xarelto®], and apixaban [Eliquis®]) should also stop taking these 
medications for at least 30 days before the attempt to restore sinus rhythm by chemical or 
DCCV. If it is unclear how long the patient has been in AF, a transesophageal echocardiogram 
may be necessary if the proper time for anticoagulation cannot be confirmed before restoring 
sinus rhythm by cardioversion. 
 
Chemical cardioversion may be achieved by the administration of flecainide, dofetilide, 
propafenone, amiodarone, dronedarone, sotalol, or ibutilide.4,5 Propafenone or flecainide is 
reasonable for patients with lone AF (no other risk factors or associated structural heart disease), 
if they are in sinus rhythm at the time of initiation.6 Starting some antiarrhythmic medication (eg, 
amiodarone or dronedarone) as an outpatient is reasonable, based on the ACCF/AHA guideline, 
for patients without heart disease and when the agent is well tolerated. However, dofetilide and 
sotalol are more prone to cause QT prolongation and thus should be initiated in the hospital, 
where continuous telemetry monitoring, 12-lead electrocardiography (ECG), and laboratory 
monitoring are available to minimize the risk of QT prolongation and subsequent risk of Torsade 
de Pointes or sudden death. Thus, it is reasonable for NPs to make referrals to the cardiology 
team to choose an optimal antiarrhythmic medication and to discuss inpatient versus outpatient 
initiation of therapy before starting the medication. 
 
Regardless of where therapy is started, rarely does antiarrhythmic medication totally eliminate 
AF. Having occasional recurrences, especially if they are self-terminating, is considered a good 
response to therapy. It is also reasonable for NPs to refer patients for catheter ablation, as an 
alternative to pharmacologic therapy, to treat symptomatic paroxysmal or persistent AF.4,6 
 
 
 
 
Prevention of Stroke and Other Thromboembolic Events 
 
Regardless of whether medication or ablation is used for rate or rhythm control, the need for 
antithrombotic therapy for stroke prevention is based on stroke risk, not whether the patient is in 
sinus rhythm. Moreover, the same criteria should be used regardless of the pattern (ie, 
paroxysmal, persistent, or permanent AF).6 Thus, NPs need to evaluate every patient with AF, 
with the exception of those with lone AF or with contraindications, for the need for 
antithrombotic therapy.6 
 
Assessing Stroke Risk in Patients with Chronic AF 
 
Because antithrombotic agents are associated with bleeding risks, NPs should stratify the risk in 
patients to determine who, given the risks and benefits, are good candidates for these 
agents.7 Research has shown that many patients who would benefit from stroke prevention do 
not always receive it. The ATRIA study found that approximately 55% of eligible insured 
patients with chronic AF who could have received warfarin for stroke prevention never got 
it.7 The percentage was higher in patients who were uninsured or elderly.7 However, placing all 
patients in AF on antithrombotic therapy is not advisable either, because the risk of major 
bleeding with these agents. 
 
One risk-stratification tool recommended by the ACCF/AHA is the CHADS2 scoring schema 
(Table 3). The CHADS2 score takes into account the stroke risk factors for patients with AF and 
assigns 1-2 points for each risk factor. Each letter in the acronym stands for the condition or 
comorbidity that has been identified as a risk factor for stroke in patients with AF. A prior stroke 
or transient ischemic attack, the highest relative risk factor for developing a future stroke, earns a 
patient 2 points, as indicated by the “S2” part of the acronym. Total CHADS2 scores may range 
from 0 to 6, with higher total scores equating with a higher likelihood of stroke risk. Patients 
with scores of 0-1 have a relatively low stroke risk, whereas, patients with the maximum score 
(6) have the highest risk of stroke.8Table 4displays the adjusted annual stroke risk based on 
CHADS2 score. 
 
Table 3. Calculating Stroke Risk Using the CHADS2 Scoring Schema 
Risk Factor Points 
Congestive heart failurea 1 
Hypertension (or treated hypertension) 1 
Age older than 75 years 1 
Diabetes 1 
Prior Stroke or transient ischemic attack 2 
a. The term congestive heart failure is being replaced by many clinicians with cardiac heart 
failure. 
Data from Furie et al.2 
 
A second, more refined risk stratification instrument, the CHA2DS2 VASc scoring schema, 
adopted by the European Society of Cardiology, may generate scores ranging from 0 to 9. As 
with the CHADS2 scores, higher scores indicate a higher stroke risk. This scoring instrument 
includes additional risk factors for stroke into the total score, assigning points for congestive HF, 
hypertension, age > 75 (2 points instead of 1), diabetes, stroke (2 points), vascular disease, age 
65-74 (1 point), and a sex category (being female).9 The inclusion of age 65-74, female gender, 
and vascular disease identifies at-risk patients who would not have been identified with the 
CHADS2 scoring schema. 
 
Table 4. Adjusted Annual Stroke Risk (Based on CHADS2 Score) 
CHADS2 Score Annual Stroke Risk 
0 1.2%-3% 
1 2%-3.8% 
2 3.1%-5.1% 
3 4.6%-7.3% 
4 6.3%-11.1% 
5 8.2%-17.5% 
6 10.5%-27.4% 
Data from Gage et al.8 
 
Stroke Prevention for Patients with Nonvalvular AF 
 
Regardless of the CHADS2 score, patients who have significant valvular heart disease or an 
artificial heart valve need chronic antithrombotic therapy, specifically warfarin. Treatment 
recommendations for patients with nonvalvular AF (patients without significant valvular heart 
disease, an artificial valve, or mitral valve repair) vary, however, depending on the 
CHADS2 score for the individual patient. 
 
The American College of Chest Physicians guideline on antithrombotic therapy, published 
annually, offers recommendations for antithrombotic stroke prophylaxis for patients with 
nonvalvular AF10 (Table 5). Based on these recommendations, patients with a CHADS2score of 
0 (low stroke risk) should not be treated with antithrombotic therapy. For those patients who 
prefer therapy, it is recommended that aspirin alone or a combination of aspirin and clopidogrel 
be used.10 For patients with a CHADS2 score of 1, oral antithrombotic therapy is recommended, 
as opposed to no therapy, aspirin alone, or the combination of aspirin and clopidogrel. However, 
which antithrombotic agent is chosen may be individualized.10 Patients with a CHADS2 score of 
> 2 should receive antithrombotic therapy, unless contraindicated, which may include warfarin or 
one of the newer antithrombotic agents discussed below. 
 
Table 5. Treatment Recommendations Stroke Prevention Based on CHADS2 Score 
CHADS2Score Stroke 
Risk 
Treatment Recommendation 
0 Low No therapy. If therapy is chosen, aspirin 
1 Moderate Oral antithrombotic therapy is recommended over aspirin or the 
combination of aspirin/clopidogrel 
≥ 2 High Oral antithrombotic therapy 
Data from You et al.10 
 
 
Current Antithrombotic Agents 
 
Vitamin K Antagonists 
 
Warfarin, a vitamin K antagonist, is relatively inexpensive and, until recently, was considered 
the best agent to prevent stroke in patients with AF. However, warfarin has 2 disadvantages: 
underutilization and difficulty in maintaining the serum blood level (ie, PT/INR) in a desired 
therapeutic range. Patients who have a subtherapeutic range are at an increased risk for 
thromboembolic events, whereas patients with INR levels above the therapeutic range are at 
increased risk for bleeding. Moreover, the inconvenience of dose titration and monitoring serum 
levels is burdensome for patients and providers. 
 
New Antithrombotic Agents 
 
Three alternative antithrombotic agents to warfarin have recently been approved by the Food and 
Drug Administration: dabigatran, rivaroxaban, and apixaban. These agents are approved for 
patients with nonvalvular AF. If chronic anticoagulation is needed for those patients, warfarin 
should be used (unless contraindicated). 
 
Common characteristics of the new agents are that they peak fairly quickly (2-4 hours), have 
shorter half-lives (5-12 hours), are out of the body sooner if discontinued (within a few hours, 
unless there is renal impairment), and have fewer drug-drug interactions compared to 
warfarin.11 In addition, the newer agents do not require dose titration or lab monitoring once 
started. However, a disadvantage of the newer agents is that they do not have an antidote for 
reversal, as is the case for warfarin. 
 
A recent indirect comparison of all 3 agents (used in nonvalvular AF patients) found that they 
offer an advantage of fewer strokes and systemic emboli and provide an addition 10% reduction 
in mortality.11 In addition, all 3 agents were associated with lower bleeding rates (including 
fewer hemorrhagic strokes, intracranial hemorrhages, and major bleeds) compared to 
warfarin.11 Refer to Table 6 for a comparison of all 4 antithrombotic agents. 
 
Table 6. Antithrombotic Treatment Options for Stroke Prevention in Nonvalvular AF 
Agent/Action Dosing 
Information 
Drug-Drug or Drug-
Food Interactions 
Management of 
Bleeding 
Key 
Implications for 
NPs 
Warfarin 
(Coumadin®) 
Vitamin K 
Antagonist 
Peak effect: 72-96 
hours 
Half-life: 40 hours 
Typically starting 
dose between 2 to 5 
mg once daily, in 
the evening 
No dosage 
adjustment with 
kidney impairment 
Many drug-drug and 
drug-food interactions 
Antidote: Vitamin K 
Concurrent use with 
other agents that alter 
coagulation factors (eg, 
aspirin, antiplatelet 
agents, chronic NSAID 
use, heparin, 
fibrinolytics) ↑ bleeding 
risk 
Requires 
ongoing lab 
monitoring. INR 
goal: 2.0-3.0 
(higher if 
mechanic valve) 
Agent/Action Dosing 
Information 
Drug-Drug or Drug-
Food Interactions 
Management of 
Bleeding 
Key 
Implications for 
NPs 
Dabigatran 
(Pradaxa®) 
Direct 
Thrombin 
Inhibitor 
(Factor IIa 
inhibitor) 
Peak effect: 2-3 
hours 
Half-life: 12-17 
hours 
Primarily 
eliminated by the 
kidneys 
Dose: 
150 mg twice daily 
(for CrCl > 30 
mg/mL) 
75 mg twice daily 
(for CrCl 15-30 
mg/mL) 
*Contraindicated if 
CrCl < 15 mL/min 
Drug-food interactions: 
None known. Take with 
or without food 
Drug-drug interactions: 
Concurrent use with 
inducers of CYP3A4 & 
P-gp (eg, rifampin, 
carbamazepine, 
phenytoin, St. John’s 
wart) ↓ exposure to the 
drug (↑ stroke risk). Co-
administration of 
rifampin and dabigatran 
should be avoided 
Concurrent use of strong 
inhibitors of CYP3A4 & 
P-gp (eg, ketoconazole, 
itraconazole, ritronavir, 
clarithromycin) ↑ 
bleeding risk. Dose of 
agent should be ↓ (75 mg 
bid) if given to patients 
with moderate kidney 
impairment (CrCl of 30-
50 mL/min) and if given 
with dronedarone or 
systemic ketoconazole 
No specific antidote. 
Concurrent use with 
other agents that alter 
coagulation factors (eg, 
aspirin, antiplatelet 
agents, chronic NSAID 
use, heparin, 
fibrinolytics) ↑ bleeding 
risk 
Minor bleeds: temporary 
discontinuation of agent 
Major bleeds: Stop the 
agent, apply direct 
pressure to compressible 
sites, give IV fluids and 
blood products (FFP 2-4 
units, RBCs, or 
prothrombin complex 
concentrate) 
Activated prothrombin 
complex or recombinant 
Factor VIIa 90 mcg/kg 
may be helpful 
Dabigatran is partially 
dialyzable. Oral/liquid 
activated charcoal may 
be considered for cases 
of overdose 
Requires no lab 
monitoring. 
Patient must be 
able to swallow 
capsules. Do not 
open, cut, or 
crush capsules 
Do not pre-fill 
pill containers 
Advise patients 
to open blister 
packs just before 
taking 
medication. Use 
all capsules 
within 4 months 
of opening bottle 
Advise patients 
if they miss a 
dose, can take 
the missed dose 
if spaced out by 
≥ 6 hours. 
Otherwise, don’t 
double doses 
Rivaroxaban 
(Xarelto®) 
Direct factor 
Xa inhibitor 
Peak effect: 2-4 
hours 
Half-life: 5-9 hours 
(healthy adults age 
2-45 years); 11-13 
hours for elders or 
those with CKD 
Partially eliminated 
by the kidneys (∼ 
33%) 
Dose: 20 mg daily 
(for CrCl ≥ 50 
mg/mL) 
15 mg daily (for 
CrCl 15-49 
Drug-food interactions: 
(for 15 or 20 mg dose): 
take with food (the 
evening meal) to 
maximize bioavailability 
Drug-drug interactions: 
Concurrent use with 
inducers of CYP3A4 & 
P-gp (eg, rifampin, 
carbamazepine, 
phenytoin, St. John’s 
wart) ↓ exposure to the 
drug (↑ stroke risk). Co-
administration of these 
agents should be avoided 
No specific antidote. 
Concurrent use with 
other agents that alter 
coagulation factors (eg, 
aspirin, antiplatelet 
agents, chronic NSAID 
use, heparin, 
fibrinolytics) ↑ bleeding 
risk 
Minor bleeds: temporary 
discontinuation of agent 
Major bleeds: same as 
dabigatran, except this 
agent is not dialyzable 
Oral/liquid activated 
Requires no lab 
monitoring 
Take with food 
(evening meal) 
If unable to 
swallow the 
tablet, it may be 
crushed and 
taken with a 
small amount of 
applesauce, 
followed by food 
Tablet may be 
crushed and 
mixed with 
Agent/Action Dosing 
Information 
Drug-Drug or Drug-
Food Interactions 
Management of 
Bleeding 
Key 
Implications for 
NPs 
mg/mL) 
*No dosing 
information if CrCl 
< 15 mL/min or if 
on dialysis 
Concurrent use of strong 
inhibitors of CYP3A4 & 
P-gp (eg, ketoconazole, 
itraconazole, ritronavir, 
clarithromycin) ↑ 
bleeding 
risk. Avoid concomitant 
use with any of these 
agents with rivaroxaban 
charcoal may be 
considered for cases of 
overdose 
water if 
administered 
through an NG 
or gastric 
feeding tube 
Apixaban 
(Eliquis®) 
Direct factor 
Xa inhibitor 
Peak effect: 3-4 
hours 
Half-life: 12 hours 
Partially eliminated 
by the kidneys 
(∼27%) 
Dose: 
5 mg twice daily 
2.5 mg twice daily 
if at least 2 of the 
following: age ≥ 80 
years, body weight 
of ≤ 60 kg, or 
serum creatinine of 
≥ 1.5 mg/dL 
*Contraindicated if 
CrCl < 25 mL/min 
Drug-food interactions: 
None known. Take with 
or without food 
Drug-drug interactions: 
Concurrent use with 
inducers of CYP3A4 & 
P-gp (eg, rifampin, 
carbamazepine, 
phenytoin, St. John’s 
wart) ↓ exposure to the 
drug (↑ stroke risk). Co-
administration of these 
agents should be avoided 
Concurrent use of strong 
inhibitors of CYP3A4 & 
P-gp (eg, ketoconazole, 
itraconazole, ritronavir, 
clarithromycin) ↑ 
bleeding risk. If any 
concurrently 
administered, a lower 
dose of apixaban should 
be prescribed (2.5 mg 
daily) 
No specific antidote 
Concurrent use with 
other agents that alter 
coagulation factors (eg 
aspirin, antiplatelet 
agents, chronic NSAID 
use, heparin, 
fibrinolytics) ↑ bleeding 
risk 
Minor bleeds: temporary 
discontinuation of agent 
Major bleeds: same as 
dabigatran, except this 
agent is not dialyzable 
Oral/liquid activated 
charcoal may be 
considered for cases of 
overdose 
Requires no lab 
monitoring 
Advise patients 
to take any 
missed dose as 
soon as possible 
on the same day 
it was originally 
scheduled. Do 
not double up on 
a missed dose if 
noted the next 
day 
CKD = chronic kidney disease; CrCl = creatinine clearance; FFP = fresh frozen plasma; INR = 
international normalized ratio; NG = nasogastric; NSAID = nonsteroidal anti-inflammatory drug; 
RBCs = red blood cells. 
Data from Boehringer Ingelheim Pharmaceuticals, Inc12; Janssen Pharmaceuticals, 
Inc13; Bristol-Myers Squibb Pharma Co14; and Bristol-Myers Squibb Co.15 
 
Contraindications to Chronic Antithrombotic Therapy 
 
Contraindications to antithrombotic therapy include active bleeding or the potential for major 
bleeding, which include blood dyscrasias, recent or anticipated surgery of the central nervous 
system, spinal puncture or other diagnostic or therapeutic procedures that have the potential for 
uncontrollable bleeding, major regional/lumbar block anesthesia, a known hypersensitivity to 
any agent under consideration, malignant hypertension, and unsupervised patients who have the 
high potential for nonadherence.12-15 
 
In addition, patients who should not receive the newer antithrombotic agents include those 
with prosthetic valves, hemodynamically significant valvular heart disease, severe kidney failure 
(eg, creatinine clearance < 15 mL/min), or advanced liver disease (eg, impaired baseline clotting 
function).12-14 Pregnant women (with the exception of those who have mechanical heart valves) 
should not be prescribed warfarin.15 Furthermore, per the packet inserts, pregnant or 
breastfeeding women should not receive the newer antithrombotic agents.12-14 
 
For patients who have contraindications to long-term antithrombotic therapy, NPs should 
consider referral for consideration for left atrial appendage closure to reduce the risk of 
stroke.16 Discussion of contemporary treatment advances in stroke prevention for this special 
population is beyond the scope of this article; however, NPs should know that options exist.16 
 
Table 7. Comparison of Bleeding Risk Scores: HEMORR2HAGES and HAS-BLED 
Scoring Schema Bleeding Risk Calculation of Bleeding Risk Score 
HEMORR2HAGES Low risk: 0-1 
points 
Moderate risk: 
2-3 points 
High risk: ≥ 4 
points 
1 point for each (except as noted): 
Hepatic or kidney disease 
Ethanol abuse 
Malignancy 
Older age (> 75) 
Reduced platelet count or function 
Re-bleeding risk (prior bleed) = 2 points 
Hypertension (uncontrolled) 
Anemia 
Genetic factors (CYP2C9 polymorphisms) 
Excessive fall risk 
Stroke 
HAS-BLED Low risk: 0 
points 
Moderate risk: 
1-2 points 
High risk: ≥ 3 
points 
Maximum score: 
9 points 
1 point for each (except as noted): 
Hypertension (uncontrolled) 
Abnormal kidney or liver function (1 point each) 
Stroke 
Bleeding history or predisposition 
Labile INR 
Elderly (age > 65) 
Drugs (concomitant use of antiplatelet/nonsteriodal anti-
inflammatory drug) or alcohol (1 point each) 
Data from You et al.10 
 
 
 
 
 
Safety Concerns of Antithrombotic Agents 
 
Bleeding Risks 
 
The primary safety concern for any antithrombotic agent is major bleeding, which may be 
classified as a fatal or a nonfatal bleed (ie, hemorrhagic stroke, intraocular bleed, and 
gastrointestinal bleed). However, NPs should keep in mind that all of these bleeding events 
combined occur infrequently (∼2-4% per year) for any of the antithrombin agents discussed 
(warfarin, dabigatran, rivaroxaban, or abixaban).11 In fact, the risk of hemorrhagic stroke, one of 
the most worrisome types of non-fatal bleeds, occurs ∼0.10%-0.47%/year, less so with the newer 
agents (0.10%-0.26%/year).11 
 
Despite the decreased likelihood of major bleeding with the use of any antithrombotic agent, NPs 
should assess the bleeding risk for their patients. Some NPs use bleeding risk scores (eg, 
HEMORR2HAGES or HAS-BLED) to evaluate the likelihood of bleeding (Table 7).17,18 These 
risk scoring schemas, however, are based on research done on warfarin. NPs need to keep in 
mind that some of the risk factors serve as an absolute or a relative contraindication to starting 
therapy (eg, a history of bleeding [the greatest risk factor], abnormal liver or kidney disease, 
uncontrolled hypertension, concomitant drug or alcohol use, reduced platelet count/function, 
excessive fall risk, and malignancy).12-15Other risk factors for bleeding, however, are also risk 
factors for having a stroke (eg, prior history of stroke, age > 65 years, and a history of 
hypertension).10 In fact, the likelihood of bleeding is higher if the patient has a higher 
CHADS2 score.19 However, NPs need to keep in mind that the chances of a stroke are higher in 
these patients than the chances that they may bleed. Thus, the likelihood of stroke takes priority 
over the likelihood of bleeding in patients with AF. 
 
Bleeding Management 
 
One of the considerations when prescribing antithrombotic therapy relates to how bleeding is 
managed. Since the newer agents have a relatively short half-life, compared to warfarin, 
temporary discontinuation of therapy may be sufficient in stopping any minor bleeds related to 
dabigatran, rivaroxaban, or apixaban. All 3 of the newer agents should be discontinued at least 
24-48 hours before elective surgery or invasive procedures that have a moderate to high risk of 
clinically significant bleeding.12-14 Longer drug-free intervals, 3 to 5 days, should be considered 
for patients who have an altered kidney function.12-14 After surgery, the medications may be 
resumed when hemostasis is obtained to avoid too long of a drug-free interval, placing the 
patient at risk for stroke.12-14 However, the packet insert and the surgeon should be consulted to 
discuss specific patient situations. 
 
For major bleeds, warfarin has a specific antidote (vitamin K). While there are no specific 
antidotes for the newer antithrombotic agents, universal antidotes for factor Xa inhibitors (eg, 
rivaroxaban and apixaban) are currently in phase 2 drug development studies.20 See Table 6 for 
the treatment of major bleeding related to the antithrombotic agents discussed. 
 
 
 
Patient Education 
 
NPs should educate all patients with AF to notify their provider should they have new or 
worsened symptoms. Patients should also be instructed to monitor for signs and symptoms of 
bleeding related to antithrombotic therapy (eg, unusual bleeding from nose or gums, heavier than 
normal menstrual bleeding, red or brown urine, red or black stools, hemoptysis, vomiting blood 
or coffee ground emesis, or unusual bruising or discoloration on the skin) and to seek help 
should any of these situations arise. 
 
In addition, NPs should provide counseling about the importance of not missing a dose of any 
medications and avoiding abrupt discontinuation of any medication (especially the new 
antithrombotic agents, as this places patients at an increased risk of stroke). If a patient is prone 
to miss an occasional dose of anti-thrombotic therapy, it is better for the NP to place him or her 
on warfarin because of a longer half-life, allowing some “coverage” for stroke prevention, 
compared to the newer agents. Regardless, patients should be instructed to contact their health 
care provider should they want to stop their medications for any reason. 
 
Educational resources are available to NPs and their patients with AF, including resources from 
the American Association of Nurse Practitioners, the National Institutes of Health, the Heart 
Rhythm Society, the American Association of Heart Failure Nurses, the National Stroke 
Association, and the Preventive Cardiovascular Nurses Association (Table 8). 
 
Table 8. Educational Materials for NPs and Patients With Atrial Fibrillation 
American Association of Nurse Practitioners 
http://www.aanp.org/education/51-education/education-toolkits/1210-heart-matters 
National Institutes of Health 
http://www.nlm.nih.gov/medlineplus/tutorials/atrialfibrillation/htm/index.htm 
Heart Rhythm Society 
http://www.hrsonline.org/Patient-Resources/Heart-Diseases-Disorders/Atrial-Fibrillation-
AFib#axzz2YnS7AZoV 
American Association of Heart Failure Nurses 
http://www.aahfnpatienteducation.com/index.php/atrial_fibrillation 
National Stroke Association 
http://www.stroke.org/site/DocServer/AFIB_toolkit_web_sm.pdf 
Preventive Cardiovascular Nurses Association 
http://pcna.net/patients/atrial-fibrillation 
 
Conclusion 
 
NPs need to provide guideline-directed medical therapy for their patients with AF. Treatment 
goals should include control of the ventricular heart rate, prevention of stroke and systemic 
embolism, and maintenance of sinus rhythm for some individuals. NPs should conduct risk 
stratification for patients with AF to determine who needs stroke prophylaxis. For those patients 
who need therapy, new treatment options are available. NPs need to weigh the pros and cons of 
using new therapy versus conventional treatment with warfarin to optimize patient outcomes. 
NPs should also err on starting chronic antithrombotic therapy in an effort to prevent stroke. 
Finally, NPs should make referrals to appropriate support services and empower their patients to 
be engaged in self-care. 
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